Eylea aflibercept ophthalmic solution: Phase III started

Last quarter, Regeneron began the double-blind, international Phase III VISTA-DME trial to compare 2 mg intravitreal Eylea given monthly or every 2 months following a monthly loading dose vs. macular ...